No ntuberculous Mycobacteria

There has been a sharp increase in the number of diseases associated with potentially pathogenic microorganisms of the genus Mycobacterium, which differ from Mycobacterium tuberculosis. These bacteria are known as atypical mycobacteria or nontuberculosis mycobacteria (NTM), and the diseases they cause are called mycobacteriosis. NTMs include more than 20 species of acid-resistant microorganisms that are widespread in the environment and that are not members of the M. tuberculosis complex. However, the role of certain types of NTMs in the pathogenesis of human diseases is rather ambiguous. The aim of the paper was to analyse the current rise in the incidence of NTM diseases, as well as the main areas of research on early diagnosis of mycobacteriosis and the detection and testing of drug susceptibility of these microorganisms. The paper summarises current views on NTM species differences, their prevalence and pathogenicity for humans and animals. The authors analysed the main efforts aimed at diagnosis and treatment of NTM diseases. The paper cites the results of the study of NTM susceptibility/resistance to anti-tuberculosis drugs. The diagnosis of mycobacteriosis remains extremely difficult, mainly because of the similarity of the clinico-radiological evidence with that of tuberculosis. Detection of NTM multiple and extensive drug resistance to the majority of anti-tuberculosis drugs complicates the treatment of the NTM disease. Further study of various aspects of NTM diseases is especially important given the increase in the incidence and prevalence of mycobacteriosis all over the world, challenging differential diagnosis, and detection of NTM extensive drug resistance.

nontuberculous mycobacteria, detection, mycobacteriosis, diagnosis, drug susceptibility, drug resistance

1. Otten TF, Vasil'ev AV. Mycobacteriosis. St. Petersburg: Meditsinskaya pressa; 2005 (In Russ.)

2. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367–416. https://doi.org/10.1164/rccm.200604-571ST

3. Brown-Elliott BA, Nash KA, Wallace RJ Jr. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria. Clin Microbiol Rev. 2012;25(3):545–82. https://doi.org/10.1128/CMR.05030-11

4. Daley CL. Mycobacterial infections. Semin Respir Crit Care Med. 2013;34(1):1–2. https://doi.org/10.1055/s-0032-1333470

5. Litvinov VI, Bogorodskaya EM, Borisov SE, eds. Non-tuberculous mycobacteria, mycobacterioses. Moscow: MNPCBT; 2014 (In Russ.)

6. Chien JY, Lai CC, Sheng WH, Yu CJ, Hsueh PR. Pulmonary infection and colonization with nontuberculous mycobacteria, Taiwan, 2000–2012. Emerg Infect Dis. 2014;20(8):1382–5. https://doi.org/10.3201/eid2008.131673

7. Adjemian J, Frankland TB, Daida YG, Honda JR, Olivier KN, Zelazny A, et al. Epidemiology of nontuberculous mycobacterial lung disease and tuberculosis, Hawaii, USA. Emerg Infect Dis. 2017;23(3):439–47. https://doi.org/10.3201/eid2303.161827

8. Henkle E, Winthrop KL. Nontuberculous mycobacteria infections in immunosuppressed hosts. Clin Chest Med. 2015;36(1):91–9. https://doi.org/10.1016/j.ccm.2014.11.002

9. McShane PJ, Glassroth J. Pulmonary disease due to nontuberculous mycobacteria: current state and new insights. Chest. 2015;148(6):1517–27. https://doi.org/10.1378/chest.15-0458

10. Stout JE, Koh WJ, Yew WW. Update on pulmonary disease due to non-tuberculous mycobacteria. Int J Infect Dis. 2016;45:123–34. https://doi.org/10.1016/j.ijid.2016.03.006

11. Larsson LO, Polverino E, Hoefsloot W, Codecasa LR, Diel R, Jenkins SG, Loebinger MR. Pulmonary disease by non-tuberculous mycobacteria – clinical management, unmet needs and future perspectives. Expert Rev Respir Med. 2017;11(12):977–89. https://doi.org/10.1080/17476348.2017.1386563

12. Brode SK, Daley CL, Marras TK. The epidemiologic relationship between tuberculosis and non-tuberculous mycobacterial disease: a systematic review. Int J Tuberc Lung Dis. 2014;18(11):1370–7. https://doi.org/10.5588/ijtld.14.0120

13. Prevots DR, Marras TK. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. Clin Chest Med. 2015;36(1):13–34. https://doi.org/10.1016/j.ccm.2014.10.002

14. Simons S, van Ingen J, Hsueh PR; Van Hung N, Dekhuijzen PN, Boeree MJ, van Soolingen D. Nontuberculous mycobacteria in respiratory tract infections, eastern Asia. Emerg Infect Dis. 2011;17(3):343–9. https://doi.org/10.3201/eid1703.100604

15. Mencarini J, Cresci C, Simonetti MT, Truppa C, Camiciottoli G, Frilli ML, et al. Non-tuberculous mycobacteria: epidemiological pattern in a reference laboratory and risk factors associated with pulmonary disease. Epidemiol Infect. 2017;145(3):515–22. https://doi.org/10.1017/S0950268816002521

16. Brown-Elliott BA, Philley JV. Rapidly growing mycobacteria. Microbiol Spectr. 2017;5(1). https://doi.org/10.1128/microbiolspec.TNMI7-0027-2016

17. Hoefsloot W, van Ingen J, Andrejak C, Angeby K, Bauriaud R, Bemer P, et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J. 2013;42(6):1604–13. https://doi.org/10.1183/09031936.00149212

18. Henry MT, Inamdar L, O’Riordain D, Schweiger M, Watson JP. Nontuberculous mycobacteria in non-HIV patients: epidemiology, treatment and response. Eur Respir J. 2004;23(5):741–6. https://doi.org/10.1183/09031936.04.00114004

19. Gerogianni I, Papala M, Kostikas K, Petinaki E, Gourgoulianis K. Epidemiology and clinical significance of mycobacterial respiratory infections in Central Greece. Int J Tuberc Lung Dis. 2008;12(7):807–12.

20. van Ingen J, Bendien SA, de Lange WC, Hoefsloot W, Dekhuijzen PN, Boeree MJ, van Soolingen D. Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, The Netherlands. Thorax. 2009;64(6):502–6. https://doi.org/10.1136/thx.2008.110957

21. Ringshausen FC, Wagner D, de Roux A, Diel R, Hohmann D, Hickstein L, et al. Prevalence of nontuberculous mycobacterial pulmonary disease, Germany, 2009–2014. Emerg Infect Dis. 2016;22(6):1102–5. https://doi.org/10.3201/eid2206.151642

22. Marras TK, Mendelson D, Marchand-Austin A, May K, Jamieson FB. Pulmonary nontuberculous mycobacterial disease, Ontario, Canada, 1998–2010. Emerg Infect Dis. 2013;19(11):1889–91. https://doi.org/10.3201/eid1911.130737

23. Morimoto K, Iwai K, Uchimura K, Okumura M, Yoshiyama T, Yoshimori K, et al. A steady increase in nontuberculous mycobacteriosis mortality and estimated prevalence in Japan. Ann Am Thorac Soc. 2014;11(1):1–8. https://doi.org/10.1513/AnnalsATS.201303-067OC

24. Shahraki AH, Heidarieh P, Bostanabad SZ, Khosravi AD, Hashemzadeh M, Khandan S, et al. "Multidrug-resistant tuberculosis" may be nontuberculous mycobacteria. Eur J Intern Med. 2015;26(4):279–84. https://doi.org/10.1016/j.ejim.2015.03.001

25. Yoon HJ, Choi HY, Ki M. Nontuberculosis mycobacterial infections at a specialized tuberculosis treatment centre in the Republic of Korea. BMC Infect Dis. 2017;17(1):432. https://doi.org/10.1186/s12879-017-2532-4

26. Shao Y, Chen C, Song H, Li G, Liu Q, Li Y, et al. The epidemiology and geographic distribution of nontuberculous mycobacteria clinical isolates from sputum samples in the eastern region of China. PLoS Negl Trop Dis. 2015;9(3):e0003623. https://doi.org/10.1371/journal.pntd.0003623

27. Falkinham JO 3rd. Environmental sources of nontuberculous mycobacteria. Clin Chest Med. 2015;36(1):35–41. https://doi.org/10.1016/j.ccm.2014.10.003

28. Halstrom S, Price P, Thomson R. Review: Environmental mycobacteria as a cause of human infection. Int J Mycobacteriol. 2015;4(2):81–91. https://doi.org/10.1128/microbiolspec.TNMI7-0024-2016

29. Koh WJ. Nontuberculous mycobacteria – overview. Microbiol Spectr. 2017;5(1). https://doi.org/10.1128/microbiolspec

30. Fedrizzi T, Meehan CJ, Grottola A, Giacobazzi E, Fregni Serpini G, Tagliazucchi S, et al. Genomic characterization of Nontuberculous Mycobacteria. Sci Rep. 2017;7:45258. https://doi.org/10.1038/srep45258

31. Tortoli E, Fedrizzi T, Meehan CJ, Trovato A, Grottola A, Giacobazzi E, et al. The new phylogeny of the genus Mycobacterium: The old and the news. Infect Genet Evol. 2017;56:19–25. https://doi.org/10.1016/j.meegid.2017.10.013

32. Chan ED, Iseman MD. Underlying host risk factors for nontuberculous mycobacterial lung disease. Semin Respir Crit Care Med. 2013;34(1):110–23. https://doi.org/10.1055/s-0033-1333573

33. Yeh JJ, Wang YC, Sung FC, Chou CY, Kao CH. Nontuberculosis mycobacterium disease is a risk factor for chronic obstructive pulmonary disease: a nationwide cohort study. Lung. 2014;192(3):403–11. https://doi.org/10.1007/s00408-014-9574-9

34. Haverkamp MH, van de Vosse E, van Dissel JT. Nontuberculous mycobacterial infections in children with inborn errors of the immune system. J Infect. 2014;68(Suppl 1):S134–50. https://doi.org/10.1016/j.jinf.2013.09.024

35. Honda JR, Knight V, Chan ED. Pathogenesis and risk factors for nontuberculous mycobacterial lung disease. Clin Chest Med. 2015;36(1):1–11. https://doi.org/10.1016/j.ccm.2014.10.001

36. Wu UI, Holland SM. Host susceptibility to non-tuberculous mycobacterial infections. Lancet Infect Dis. 2015;15(8):968–80. https://doi.org/10.1016/S1473-3099(15)00089-4

37. Lipner EM, Garcia BJ, Strong M. Network analysis of human genes influencing susceptibility to mycobacterial infections. PLoS One. 2016;11(1):e0146585. https://doi.org/10.1371/journal.pone.0146585

38. Weiss CH, Glassroth J. Pulmonary disease caused by nontuberculous mycobacteria. Expert Rev Respir Med. 2012;6(6):597–612. https://doi.org/10.1586/ers.12.58

39. Guarner J. Buruli Ulcer: Review of a neglected skin mycobacterial disease. J Clin Microbiol. 2018;56(4):e01507-17. https://doi.org/10.1128/JCM.01507-17

40. Yano Y, Kitada S, Mori M, Kagami S, Taguri T, Uenami T, et al. Pulmonary disease caused by rapidly growing mycobacteria: a retrospective study of 44 cases in Japan. Respiration. 2013;85(4):305–11. https://doi.org/10.1159/000339631

41. Jeong SH, Kim SY, Huh HJ, Ki CS, Lee NY, Kang CI, et al. Mycobacteriological characteristics and treatment outcomes in extrapulmonary Mycobacterium abscessus complex infections. Int J Infect Dis. 2017;60:49–56. https://doi.org/10.1016/j.ijid.2017.05.007

42. van Ingen J. Microbiological diagnosis of nontuberculous mycobacterial pulmonary disease. Clin Chest Med. 2015;36(1):43–54. https://doi.org/10.1016/j.ccm.2014.11.005

43. Cowman S, van Ingen J, Griffith DE, Loebinger MR. Non-tuberculous mycobacterial pulmonary disease. Eur Respir J. 2019;54(1):1900250. https://doi.org/10.1183/13993003.00250-2019

44. Richter E, Andres S, Hillemann D. Current microbiological methods in the investigation of mycobacteria. Pneumologie. 2015;69(5):276–81. https://doi.org/10.1055/s-0034-1391960

45. Fleshner M, Olivier KN, Shaw PA, Adjemian J, Strollo S, Claypool RJ, et al. Mortality among patients with pulmonary non-tuberculous mycobacteria disease. Int J Tuberc Lung Dis. 2016;20(5):582–7. https://doi.org/10.5588/ijtld.15.0807

46. Heifets L. Drug susceptibility in the chemotherapy of mycobacterial infections. Boca Raton, Ann Arbor, Boston, London: CRC Press; 2000.

47. van Ingen J, Boeree MJ, van Soolingen D, Mouton JW. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. Drug Resist Updat. 2012;15(3):149–61. https://doi.org/10.1016/j.drup.2012.04.001

48. Philley JV, Griffith DE. Medical management of pulmonary nontuberculous mycobacterial disease. Thorac Surg Clin. 2019;29(1):65–76. https://doi.org/10.1016/j.thorsurg.2018.09.001

49. Litvinov V, Makarova M, Galkina K, Khachaturiants E, Krasnova M, Guntupova L, Safonova S. Drug susceptibility testing of slowly growing non-tuberculous mycobacteria using slomyco test-system. PLoS One. 2018;13(9):e0203108. https://doi.org/10.1371/journal.pone.0203108

50. Makarova MV, Khachaturiants EN, Krasnova MA, Safonova SG, Khakhalina AA, Chizhova AO, Litvinov VI. Drug susceptibility of M. chelonae-abscessus complex. Tuberkulez i sotsial'no znachimye zabolevaniya = Tuberculosis and Socially Significant Diseases. 2018;(2):22–30 (In Russ.)

51. Makarova MV, Safonova SG, Mikhaylova YuD, Guntupova LD, Chizhova AO, Litvinov VI. The study of drug sensitivity Mycobacterium fortuitum complex. Tuberkulez i sotsial'no znachimye zabolevaniya = Tuberculosis and Socially Significant Diseases. 2018;(4):20–7 (In Russ.)

52. Makarova MV, Khachaturyants EN, Krasnova MA. Drug susceptibility of nontuberculous mycobacteria. Tuberkulez i bolezni legkikh = Tuberculosis and Lung Diseases. 2011;88(6):51–5 (In Russ.)